Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

RCKT 12.10.2024

Full Press ReleaseSEC FilingsOur RCKT Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.02.2025 - Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.31.2024 - Yun Zhong

Recent Filings

  • 12.16.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.16.2024 - SC 13D/A General Statement of Acquisition of Beneficial Ownership
  • 12.12.2024 - 8-K Current report

CRANBURY, N.J.--(BUSINESS WIRE)--Dec. 10, 2024--Rocket Pharmaceuticals, Inc.(NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today that it intends to offer and sell$150 millionof shares of its common stock in an underwritten public offering. In addition, Rocket intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Morgan Stanley,Leerink Partnersand Cantor are acting as joint book-running managers for the offering, andLifeSci Capitalis acting as lead manager for the offering.

The shares are being offered by Rocket pursuant to an effective shelf registration statement that was previously filed with theU.S. Securities and Exchange Commission(the “SEC”). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with theSECand will be available on the SEC’s website athttp://www.sec.gov.

When available, copies of the prospectus supplement relating to the offering may be obtained fromMorgan Stanley & Co. LLC, Attention: Prospectus Department,180 Varick Street, 2nd Floor,New York, New York10014, by email atprospectus@morganstanley.com;Leerink Partners LLC,Syndicate Department,53 State Street, 40th Floor,Boston, MA02109, or by telephone at (800) 808-7525 ext. 6105 or by email atsyndicate@leerink.com; orCantor Fitzgerald & Co., Attention: Capital Markets,110 East 59th Street, 6th Floor,New York, New York, 10022, or by email atprospectus@cantor.com. You may also obtain a copy of this document free of charge by visiting the SEC’s website athttp://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

AboutRocket Pharmaceuticals, Inc.Rocket Pharmaceuticals, Inc.(NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.

Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.

Rocket’s adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles.

Rocket Cautionary Statement Regarding Forward-Looking StatementsVarious statements in this release concerning the timing and completion of the public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Rocket’s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Rocket’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled "Risk Factors" in the prospectus supplement and registration statement referenced above, Rocket’s Annual Report on Form 10-K for the year endedDecember 31, 2023, filedFebruary 27, 2024with theSECand subsequent filings with theSECincluding our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that Rocket will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241210060247/en/

Media & InvestorsMeg Dodgemdodge@rocketpharma.com

MediaKevin Giordanomedia@rocketpharma.com

InvestorsBrooks Rahmerinvestors@rocketpharma.com

Source:Rocket Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com